Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2004
Business Overview: The Company operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industry. Key products include First Defense and Wipe Out Dairy Wipes. The Company is currently developing Mast Out, a new product utilizing Nisin for the treatment of mastitis.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2004 | Six Months Ended June 30, 2003 |
|---|---|---|
| Total Revenues | $1,907,018 | $1,743,977 |
| Net Income | $114,136 | $576,992 |
| Net Income Per Share (Diluted) | $0.04 | $0.21 |
| Gross Margin % (Product Sales) | 59% | 56% |
| Operating Cash Flow | $237,685 | $1,298,075 |
| Cash and Short-Term Investments | $4,302,986 | $4,245,062 |
| Total Assets | $8,135,907 | $8,186,632 |
| Total Liabilities | $615,353 | $816,180 |
| Shareholders' Equity | $7,520,554 | $7,370,452 |
Note: The 2003 Net Income included a one-time $1,100,000 gain from the sale of a joint venture interest.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9% year-over-year for the six-month period, driven by a 16% increase in product sales. Sales of First Defense increased 24%, while Wipe Out Dairy Wipes sales decreased 2%.
- Profitability: Net income decreased significantly to $114,136 from $576,992 in the prior year. The prior year figure was inflated by a $1,100,000 non-recurring gain from the sale of a joint venture. Excluding this item, the Company's core operations showed improved profitability with a net operating income of $169,478 compared to a loss of $144,088 in the prior year.
- Expense Management: Research and development (R&D) expenses decreased 23% to $463,233. General and administrative expenses remained relatively flat, while product selling expenses decreased 22%.
- Liquidity: Cash and cash equivalents decreased by $1.8 million, while short-term investments increased by $1.9 million, resulting in a net increase in total liquid assets of $58,000. Net working capital increased by $133,000.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Mast Out Development: The Company achieved positive results from an experimental field trial of Mast Out in January 2004. A pivotal efficacy trial is intended to be initiated in 2004. Management anticipates higher R&D expenditures later in the year for this trial, which may result in net losses for 2004 and 2005.
- Manufacturing: In July 2004, the Company completed facility modifications to produce Nisin in-house, eliminating reliance on a subcontractor. This is expected to improve quality control and reduce production costs.
- Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for at least the next twelve months.
- Grants: The Company received a second Development Award of up to $500,000 from the Maine Technology Institute in June 2004, pending final documentation.
Risks and Contingencies
- Regulatory Approval: Future growth is heavily dependent on the successful development and FDA approval of Mast Out. There is no assurance that the product will be found efficacious or gain approval.
- Market Risks: The dairy industry faces economic pressures. While milk prices have recently improved, financial insecurity among customers remains a risk.
- Supply Chain: The Company is heavily dependent on its single manufacturing facility in Portland, Maine. Disruptions could negatively affect production.
- Biological Threats: Risks include epidemics of bovine diseases (e.g., BSE) and potential bioterrorism, which could impact raw material acquisition and customer health.
Investor Verification Checklist
- One-Time Gains: Verify the exclusion of the $1.1 million joint venture sale gain from 2003 when comparing year-over-year profitability.
- R&D Spend Trajectory: Monitor upcoming quarters for the anticipated increase in R&D expenses related to the pivotal Mast Out trial and its impact on net income.
- Grant Funding: Confirm the receipt and terms of the second $500,000 Development Award from the Maine Technology Institute.
- Customer Concentration: Note that one distributor accounted for 19% of total product sales in the six months ended June 30, 2004.
- Regulatory Status: Track the progress of the Mast Out pivotal trial and the timeline for the anticipated FDA filing in the first half of 2006.